Illumina's new patent infringement suit targets Complete Genomics' cPal read technology

Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.

The new suit, filed in the U.S. District Court for the Southern District of California, is based on Complete Genomics' infringement of U.S. Patent No. 8,192,930, entitled "Method for Sequencing a Polynucleotide Template." The suit targets Complete Genomics' Combinatorial Probe-Anchor Ligation (cPal) read technology.

Illumina previously sued Complete Genomics for infringement of U.S. Patent No. 6,306,597, in the U.S. District Court for the Northern District of California. On February 8, 2012, the Court in that case issued a Claim Construction Order providing the Court's interpretation of the disputed patent terms which affirmed the breadth of the patent and supports Illumina's position that Complete Genomics infringes that patent.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S. and many additional patents granted worldwide.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 24). Illumina's new patent infringement suit targets Complete Genomics' cPal read technology. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20120618/Illuminas-new-patent-infringement-suit-targets-Complete-Genomics-cPal-read-technology.aspx.

  • MLA

    Illumina, Inc.. "Illumina's new patent infringement suit targets Complete Genomics' cPal read technology". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20120618/Illuminas-new-patent-infringement-suit-targets-Complete-Genomics-cPal-read-technology.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina's new patent infringement suit targets Complete Genomics' cPal read technology". News-Medical. https://www.news-medical.net/news/20120618/Illuminas-new-patent-infringement-suit-targets-Complete-Genomics-cPal-read-technology.aspx. (accessed October 31, 2024).

  • Harvard

    Illumina, Inc.. 2019. Illumina's new patent infringement suit targets Complete Genomics' cPal read technology. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20120618/Illuminas-new-patent-infringement-suit-targets-Complete-Genomics-cPal-read-technology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Illumina's board appoints Jacob Thaysen, Ph.D. as its new Chief Executive Officer